CDH1 and neoplasm: We modeled mixed effects in the setting of multiple simultaneous tumors, and identified EGFR as a clinical target activated by tumor stromal cells that limits the growth of highly proliferating, metastatic, E-cadherin-positive cells in this IBC xenograft model.